A cohort study investigating the occurrence of differences in care provided to men and women in an intensive care unit

Erik Zettersten1,2, Gabriella Jäderling1,2, Max Bell1,2 & Emma Larsson1,2

It has been reported that there are differences in the care given within the intensive care unit (ICU) between men and women. The aim of this study is to investigate if any differences still exist between men and women regarding the level of intensive care provided, using prespecified intensive care items. This is a retrospective cohort study of 9017 ICU patients admitted to a university hospital between 2006 and 2016. Differences in use of mechanical ventilation, invasive monitoring, vasoactive treatment, inotropic treatment, echocardiography, renal replacement therapy and central venous catheters based on the sex of the patient were analysed using univariate and multivariable logistic regressions. Subgroup analyses were performed on patients diagnosed with sepsis, cardiac arrest and respiratory disease. Approximately one third of the patients were women. Overall, men received more mechanical ventilation, more dialysis and more vasoactive treatment. Among patients admitted with a respiratory disease, men were more likely to receive mechanical ventilation. Furthermore, men were more likely to receive levosimendan if admitted with cardiac arrest. We conclude that differences in the level of intensive care provided to men and women still exist.

Abbreviations
ICU  Intensive Care Unit
LOS  Length of stay
CCI  Charlson Comorbidity Index
SAPS3  Simplified Acute Physiology Score 3
APACHE II  Acute Physiology And Chronic Health Evaluation II
SOFA  Sequential Organ Failure Assessment
KARDA  Karolinska Database
CVC  Central venous catheter
ALI  Acute lung injury
ARDS  Acute respiratory distress syndrome
MAP  Mean arterial pressure
AKI  Acute kidney injury
RRT  Renal replacement therapy

Historically, it has been reported that more men than women are treated in the Intensive Care Unit (ICU)1–5 and that once admitted, men receive more mechanical ventilation, vasoactive drugs, renal replacement therapy (RRT) and invasive monitoring6–8. Furthermore, there are indications that men have a longer length of stay (LOS) in the ICU9. These reported differences do not seem to translate into a survival benefit for men, previous studies have shown conflicting results with no clear sex difference between men and women in survival1,4,6. It is not fully understood why gender discrepancies in ICU-treated patients exist. It is proposed that sex hormones have an impact on how the severity of an illness progresses, where female sex hormones are suggested to have

1Perioperative Medicine and Intensive Care, Karolinska University Hospital, Solna, Stockholm, Sweden. 2Section of Anaesthesiology and Intensive Care Medicine, Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden. *email: erik.zettersten@regionstockholm.se
a protective effect, showing lower risk of sepsis and better outcome after major bleeding and trauma in animal models. That could possibly be a part of the explanation to the male dominance in ICU populations; women don’t develop critical illness in the same manner as men. However, data regarding the influence of sex hormones on the course of illness are conflicting. We do not have evidence that medical care given in the ICU should be tailored after the sex of the patient. Then again, there is no clear evidence that the medical care should not be tailored after the sex of the patient. Therefore, differing care provided to men and women is still controversial. If differences exist, it has to be ruled out that it is caused by gender bias, unintentional or not. The question remains as to why men have an apparent greater need of intensive care, as indicated by the larger proportion of men in the ICU. Our group has previously investigated the afferent arm, i.e., if there are any differences in admittance to the ICU, and the efferent arm, i.e., mortality and discharge patterns from the ICU in an effort to understand the ICU sex ratio. For this study, we aimed at investigating if there were any differences in the intensity of intensive care in a cohort of more than 9000 patients cared for at a university hospital. Our hypothesis is that given equal disease burden, men receive more intensive care in the ICU.

Methods
Setting and study population. This retrospective cohort study was conducted at a mixed 13-bed ICU at the Karolinska University Hospital, Stockholm, Sweden. Medical and surgical patients are treated in this ICU, including trauma patients. Cardiothoracic, neurosurgical and paediatric patients are treated in separate ICUs and not included in the current study. Eligible for inclusion were patients ≥ 18 years old treated in the ICU between January 2006 and December 2016. After exclusion of patients < 18 years (n = 234) and patients not found when cross-matching with Karolinska Database (KARDA) (n = 555 of which 36.6% were women) 9017 patients were included in the analysis. Our research group has previously analysed this dataset with the aim of investigating length of stay and 30- and 90-day mortality.

Data collection. All patients are registered in the electronic ICU patient data management system (PDMS, Clinisoft, GE Healthcare) from which we extracted data on admission diagnosis codes, Acute Physiology And Chronic Health Evaluation (APACHE II) score, Simplified Acute Physiology Score (SAPS 3), all codes for any therapy given within the ICU (invasive ventilation, invasive monitoring, vasoactive medication and renal replacement therapy) as well as time of admission, discharge and readmissions. Demographic data, comorbidities and 30- and 90-day mortality were extracted from KARDA.

Outcomes. Primary outcome was sex difference in any of the items decided a priori as proxy for intensity of intensive care. The following items were included: invasive mechanical ventilation, invasive monitoring, central venous catheter placement, renal replacement therapy, echocardiography, presence of one vasoactive or inotropic drug and presence of more than one vasoactive or inotropic drug. Each outcome is considered separately.

Definitions. Sex is broadly defined as either of the two main categories (male and female) into which humans and most other living species are divided on the basis of their reproductive functions. Gender is defined by the World Health Organisation as the socially constructed roles, behaviours, activities and attributes that a given society considers appropriate for men and women. For this study, we had access to the patient’s social security number, in which it is registered if the patient is defined as a man or a woman. All analyses are performed using the social security number, i.e. the gender of the patient. We aim at using the term sex when discussing biological differences between patients, and gender when discussing reasons for why patients are treated differently depending on whether they are defined as a man or a woman in their social security number. It is important to note that a person might change their social security number depending on how they identify themselves. Patients were assumed to be mechanically ventilated if they presented any of the codes for intubation orally or nasally, ventilator treatment, inhalation anaesthesia or high frequency oscillation ventilation. Invasive monitoring was defined as the presence of a pulmonary artery catheter and it was included as an item if any codes for pulmonary artery catheterization were present. Central venous catheter (CVC) was included as an item if the code for placement of a CVC was present, it was not included as an item if only code for use of CVC was present. Renal replacement therapy was assumed when codes for continuous renal replacement therapy were present, or when code for central dialysis catheter placement was present. Echocardiography codes included both trans-thoracic and transoesophageal echocardiography. Vasoactive medication included norepinephrine and epinephrine as there is no significant use of other vasoactive agents at the Karolinska Hospital ICU. Inotropic medication included levosimendan and milrinone only, for the same reason. In 2010, Karolinska Hospital Solna replaced APACHE II with SAPS 3. We therefore calculated Estimated mortality risk (EMR) from the APACHE II and SAPS 3 scores using their specific formulas to be a proxy for severity of illness at admission.

Statistical analysis. Continuous variables were compared using Wilcoxon rank-sum test and presented as median and interquartile range (IQR). Comparison of categorical variables was performed using Pearson’s Chi-squared test. The association between men and women and use of intensive care resources was analysed using univariate and multivariable logistic regression. Variables in the multivariable model were selected a priori and included age, estimated mortality risk and Charlson Comorbidity Index (CCI). Subgroup analyses were performed on patients diagnosed with sepsis, cardiac arrest and respiratory disease. Results are presented as odds-ratio (OR) and corresponding 95% confidence interval.
Ethics. The Regional Ethical Review Board in Stockholm, Sweden approved the study (Registration Number 2014/756-31/1). The invasion of privacy in this anonymized retrospective register-based study is considered to be acceptable in relation to the potential benefits the project may bring to these patient categories. Patient consent was therefore waived according to the ethical approval from the Regional Ethical Review Board in Stockholm, Sweden. All research was conducted in accordance with national guidelines and regulations.

Results

Patient demographics. In total 9017 patients were included in the study. There were more men than women admitted to the ICU, with a male dominance of 63.5%. Demographic data are presented in Table 1. Median [IQR] age (61 [41–72] vs. 59 [41–70]; p = 0.001) and estimated mortality risk (11.1 [3.1–29.9] vs. 9.9 [2.9–29.1]; p = 0.03) were statistically higher in women. Median [IQR] CCI was slightly higher in men (2 [2–4] vs. 2 [2–4]; p = 0.03). There was no statistical difference between women and men regarding SAPS 3 or APACHE II scores. According to admission diagnosis, women were more likely to be admitted with a respiratory disease (22.6% of the women vs. 18.2% of the men; p < 0.001), neurological disease (2.2% vs. 1.4%; p = 0.01), intoxication (5.5% vs. 4.4%; p = 0.018), sepsis (12.7% vs. 10.2%; p = 0.004) or other (7.4% vs. 5.5%; p = 0.000) whilst men were more likely to be trauma patients (30.0% of the men vs. 15.9% of the women; p = 0.000). A sensitivity analysis conducted on patients not found in Karda revealed similar age and gender distribution (men 62.7%, median [IQR] age 60 [46–70], women 37.2 median [IQR] age 63 [47–73]) compared to included patients.

Intensity of intensive care. Overall, men were more likely to receive mechanical ventilation [OR 1.28 (95% CI 1.17–1.41)], vasoactive treatment [OR 1.16 (95% CI 1.06–1.27)] and RRT (intermittent haemodialysis or continuous renal replacement therapy) [OR 1.21 (95% CI 1.04–1.40)] (Table 2). In additional subgroup analyses, men were more likely to be administered levosimendan if admitted to ICU with sepsis [OR 1.45 (95% CI 1.03–2.04)] or cardiac arrest [OR 2.11 (95% CI 1.27–3.49)]. If admitted with a cardiac arrest diagnosis, men more often received a central venous line [1.60 (95% CI 1.04–2.45)] (Tables 3 and 4). Men were also more likely

|       | Women | Men | p* |
|-------|-------|-----|----|
| Sex (n = 9017) | 3289 (36.5) | 5728 (63.5) |    |
| Age median (IQR) (n = 9017) | 61 [41–72] | 59 [41–70] | 0.001 |
| Age (%) |       |     |    |
| <40 | 796 (24.2) | 1375 (24.0) |    |
| 41–60 | 811 (24.7) | 1631 (28.5) |    |
| 61–80 | 1344 (40.9) | 2330 (40.7) |    |
| 81–90 | 309 (9.4) | 375 (6.6) |    |
| 91–110 | 29 (0.9) | 17 (0.3) |    |
| CCI, median (IQR) | 20–4) | 2 (0–4) | 0.03 |
| CCI categories |       |     |    |
| 0 | 1059 (32.1) | 1955 (33.9) |    |
| 1–2 | 981 (29.7) | 1654 (28.7) |    |
| 3–4 | 481 (14.6) | 889 (15.4) |    |
| >5 | 780 (23.6) | 1268 (22.0) |    |
| SAPS 3, median (IQR) (n = 6359) | 55 (42–68) | 54 (41–68) | 0.73 |
| APACHE II, median (IQR) (n = 4251) | 11 (6–18) | 11 (6–17) | 0.59 |
| EMR, median (IQR) (n = 8898) | 11.1 (3.1–29.9) | 9.9 (2.9–29.1) | 0.03 |
| ICU diagnosis, No. (%) |       |     |    |
| Cardiovascular | 490 (14.8) | 894 (15.5) | 0.4 |
| Respiratory | 746 (22.6) | 1053 (18.2) | 0.000 |
| Gastrointestinal | 204 (6.2) | 354 (6.1) | 0.93 |
| Renal | 53 (1.6) | 100 (1.7) | 0.65 |
| Sepsis/septic shock | 419 (12.7) | 617 (10.2) | 0.004 |
| Neurological | 71 (2.2) | 82 (1.4) | 0.01 |
| Trauma | 526 (15.9) | 1731 (30.0) | 0.000 |
| Intoxication | 183 (5.5) | 256 (4.4) | 0.018 |
| Other | 246 (7.4) | 316 (5.5) | 0.000 |

Table 1. Patient characteristics. Continuous parameters presented as median (IQR). Categorical parameters presented as number (%) unless indicated otherwise. CCI Charlson Co-morbidity Index; SAPS 3 Simplified Acute Physiology Score; APACHE II Acute physiology and chronic health evaluation; IQR Interquartile Range; ICU Intensive care unit; EMR Estimated Mortality Risk. *Wilcoxon rank-sum test, ^Chi-square test.
Table 2. Univariate and multivariable logistic regression analyses on all patients, exploring differences in the use of invasive mechanical ventilation, invasive monitoring, vasoactive treatment, echocardiography, RRT and placement of central catheters, based on the sex of the patient. Data presented as odds ratio and 95% CI. a 9067 and 8863 patients are included in univariate analyses and multivariable analysis respectively. b Adjusted for Age, Estimated mortality risk and Charlson Co-morbidity index. RRT Renal replacement therapy.

|                      | Univariate | Multivariable |
|----------------------|------------|---------------|
| **Invasive mechanical ventilation** |            |               |
| Women                 | Ref        | Ref           |
| Men                   | 1.27 (95% CI 1.16–1.38) | 1.28 (95% CI 1.17–1.41) |
| **Invasive monitoring** |            |               |
| Women                 | Ref        | Ref           |
| Men                   | 1.09 (95% CI 0.81–1.48) | 1.09 (95% CI 0.80–1.49) |
| **Vasoactive treatment** |          |               |
| Women                 | Ref        | Ref           |
| Men                   | 1.12 (95% CI 1.02–1.21) | 1.16 (95% CI 1.06–1.27) |
| **Echocardiography**  |            |               |
| Women                 | Ref        | Ref           |
| Men                   | 0.96 (95% CI 0.87–1.06) | 0.96 (95% CI 0.87–1.06) |
| **RRT**               |            |               |
| Women                 | Ref        | Ref           |
| Men                   | 1.22 (95% CI 1.06–1.41) | 1.21 (95% CI 1.04–1.40) |
| **Central catheters** |            |               |
| Women                 | Ref        | Ref           |
| Men                   | 1.04 (95% CI 0.95–1.13) | 1.09 (95% CI 0.99–1.19) |

Table 3. Univariate and multivariate logistic regression analyses on patients admitted with sepsis, exploring differences in the use of invasive mechanical ventilation, invasive monitoring, vasoactive treatment, echocardiography, RRT and placement of central catheters, based on the sex of the patient. Data presented as odds ratio and 95% CI. a 1036 and 1007 patients are included in univariate analyses and multivariable analyses respectively. b Adjusted for Age, Estimated mortality risk and Charlson Co-morbidity index. RRT Renal replacement therapy.

|                      | Univariate | Multivariable |
|----------------------|------------|---------------|
| **Invasive mechanical ventilation** |            |               |
| Women                 | Ref        | Ref           |
| Men                   | 1.01 (95% CI 0.79–1.30) | 1.00 (95% CI 0.77–1.29) |
| **Invasive monitoring** |            |               |
| Women                 | Ref        | Ref           |
| Men                   | 1.10 (95% CI 0.67–1.83) | 1.12 (95% CI 0.67–1.88) |
| **Vasoactive treatment** |          |               |
| Women                 | Ref        | Ref           |
| Men                   | 1.18 (95% CI 0.87–1.59) | 1.12 (95% CI 0.82–1.53) |
| **Echocardiography**  |            |               |
| Women                 | Ref        | Ref           |
| Men                   | 0.82 (95% CI 0.64–1.06) | 0.77 (95% CI 0.59–1.00) |
| **RRT**               |            |               |
| Women                 | Ref        | Ref           |
| Men                   | 1.27 (95% CI 0.96–1.68) | 1.22 (95% CI 0.91–1.65) |
| **Central catheters** |            |               |
| Women                 | Ref        | Ref           |
| Men                   | 0.97 (95% CI 0.67–1.40) | 0.87 (95% CI 0.59–1.28) |
| **Levosimendan**      |            |               |
| Women                 | Ref        | Ref           |
| Men                   | 1.44 (95% CI 1.03–2.00) | 1.43 (95% CI 1.03–2.04) |
Table 4. Univariate and multivariate logistic regression analyses on patients admitted with cardiac arrest, exploring differences in the use of invasive mechanical ventilation, invasive monitoring, vasoactive treatment, echocardiography, RRT and placement of central catheters, based on the sex of the patient. Data presented as odds ratio and 95% CI. a 536 and 529 patients are included in univariate analyses and multivariable analyses respectively. b Adjusted for Age, Estimated mortality risk and Charlson Co-morbidity index. RRT Renal replacement therapy.

|                          | Univariate* | Multivariableb |
|--------------------------|-------------|-----------------|
| **Invasive mechanical ventilation** |             |                 |
| Women                    | Ref         | Ref             |
| Men                      | 1.24 (95% CI 0.59–2.58) | 1.16 (95% CI 0.54–2.50) |
| **Invasive monitoring**  |             |                 |
| Women                    | Ref         | Ref             |
| Men                      | 1.67 (95% CI 0.54–5.14) | 1.72 (95% CI 0.55–5.33) |
| **Vasoactive treatment** |             |                 |
| Women                    | Ref         | Ref             |
| Men                      | 1.46 (95% CI 0.94–2.26) | 1.50 (95% CI 0.96–2.33) |
| **Echocardiography**     |             |                 |
| Women                    | Ref         | Ref             |
| Men                      | 1.14 (95% CI 0.79–1.65) | 1.16 (95% CI 0.80–1.68) |
| **RRT**                  |             |                 |
| Women                    | Ref         | Ref             |
| Men                      | 1.32 (95% CI 0.74–2.34) | 1.39 (95% CI 0.77–2.50) |
| **Central catheters**    |             |                 |
| Women                    | Ref         | Ref             |
| Men                      | 1.59 (95% CI 1.04–2.42) | 1.60 (95% CI 1.04–2.45) |
| **Levosimendan**         |             |                 |
| Women                    | Ref         | Ref             |
| Men                      | 2.04 (95% CI 1.24–3.37) | 2.11 (95% CI 1.27–3.49) |

Table 5. Univariate and multivariate logistic regression analyses on patients admitted with respiratory disease, exploring differences in the use of invasive mechanical ventilation, invasive monitoring, vasoactive treatment, echocardiography, RRT and placement of central catheters, based on the sex of the patient. Data presented as odds ratio and 95% CI. a 1799 and 1769 patients are included in univariate analyses and multivariable analyses respectively. b Adjusted for Age, Estimated mortality risk and Charlson Co-morbidity index. RRT Renal replacement therapy.

|                          | Univariate* | Multivariableb |
|--------------------------|-------------|-----------------|
| **Invasive mechanical ventilation** |             |                 |
| Women                    | Ref         | Ref             |
| Men                      | 1.25 (95% CI 1.03–1.50) | 1.22 (95% CI 1.01–1.49) |
| **Invasive monitoring**  |             |                 |
| Women                    | Ref         | Ref             |
| Men                      | 1.21 (95% CI 0.55–2.65) | 1.11 (95% CI 0.49–2.47) |
| **Vasoactive treatment** |             |                 |
| Women                    | Ref         | Ref             |
| Men                      | 1.19 (95% CI 0.99–1.44) | 1.12 (95% CI 0.91–1.38) |
| **Echocardiography**     |             |                 |
| Women                    | Ref         | Ref             |
| Men                      | 0.98 (95% CI 0.80–1.21) | 0.90 (95% CI 0.72–1.12) |
| **RRT**                  |             |                 |
| Women                    | Ref         | Ref             |
| Men                      | 1.57 (95% CI 1.10–2.23) | 1.39 (95% CI 0.97–2.01) |
| **Central catheters**    |             |                 |
| Women                    | Ref         | Ref             |
| Men                      | 1.06 (95% CI 0.88–1.28) | 0.99 (95% CI 0.80–1.21) |
to receive mechanical ventilation [1.22 (95% CI 1.01–1.49)] if admitted with a respiratory diagnosis (Table 5).

Women were not more likely to receive any of the items investigated.

Discussion

The results from this cohort study of 9017 ICU patients indicate that men received more intensive care in the ICU, given equal burden of disease to women at admission. The causes for this are unclear, but men might have a more severe trajectory in their course of disease, as compared to women. In general, men received more mechanical ventilation, vasoactive treatment and RRT. When performing subgroup analyses we found that men admitted with a respiratory diagnosis received more mechanical ventilation, and that men admitted with sepsis or cardiac arrest received more inotropic treatment in the form of levosimendan. Interestingly, none of the items investigated were more likely to be provided to women.

Similar results have been previously reported[1–3,17]. Most noteworthy is the work by Valentin[2] and Fowler[3], two large multicenter studies. Both concluded that women received less intensive care when in the ICU. Our group has previously investigated if the sex of the patient had any impact on physicians’ willingness to admit patients to the ICU. We found no evidence supporting patient sex to be a factor in admitting patients[12,13]. In a follow-up study we showed that given equal disease burden as women, men had a lower probability of being discharged from the ICU[6]. The question remains whether women would have a survival benefit if treated exactly in the same manner as men. There are plausible explanations as to why men receive slightly more intensive care than women. This will be discussed below.

Mechanical ventilation. Men seem to follow a different path than women regarding the progression of sepsis and respiratory illness. It appears as if men develop more severe sepsis[18] and respiratory illness[19] compared to women. By now there is considerable evidence supporting the role of estrogen as a mediator in the production of proinflammatory cytokines, namely IL-1, IL-6 and TNF-α[20] and at least there are plausible explanations for differences in development of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) where different pathways have been described, resulting in less barrier dysfunction and inflammation in female rat lungs[19]. Similar results have been presented for the development of sepsis, where men had increased levels of TNF-α and decreased levels of IL-10 as compared to women[21].

Vasoactive treatment. In this study we found that men received more vasoactive treatment compared to women. The reason for this is most likely multifactorial. One interesting explanation could be different vascular response to illness, mediated in part by estrogen. The effect of estrogen on the cardiovascular system is still not clearly understood, but there are interesting animal models showing improved heart function[22] and differences in vasoreactivity. Li et al. have investigated vasoreactivity in healthy humans and rats and found that premenopausal women had a stronger responsiveness compared to men and postmenopausal women. These results were strengthened by their rat model, where they found that male rats lost more of their vascular reactivity compared to female rats following haemorrhagic trauma. Infusion of exogen 17-β estradiol increased MAP and animal survival[23].

Renal replacement therapy. We found that men received more RRT than women. This is in line with previous research. In a very large study of approximately 195,000,000 patients from the United Kingdom[24], men were 2.2 times more likely to develop acute kidney injury (AKI). Neugarten et al. used intervention and procedure codes for hemodialysis and hemofiltration as proxy for AKI, which introduces the possibility that they in fact investigated discrepancies in utilization of dialysis between men and women and not development of AKI. Supporting their argument are several studies that report either no difference in initiation of RRT given equal level of AKI between men and women, or that women were more likely to receive RRT[25–27]. Furthermore, there are compelling animal models supporting a protective role of estrogen in development of AKI after severe illness[28–30].

Inotropic treatment. Levosimendan is a positive inotropic drug primarily indicated for short term use in patients with heart failure and acutely diminished heart function. Its role in sepsis has been disputed recently[31,32], but in selected cases it can still be a part of the treatment arsenal. Its use following cardiac arrest is still controversial, but animal studies suggest a beneficial effect[33]. So why then do men receive more levosimendan following cardiac arrest? One possible explanation could be that it is more common for men to develop macrovascular coronary artery disease, commonly leading to heart failure with reduced ejection fraction (HFrEF) while women are more prone to develop endothelial inflammation, leading to microvascular dysfunction, which in turn leads to heart failure with preserved ejection fraction (HFpEF)[34]. Furthermore, Iorga et al. introduced a rat model where they managed to preserve ejection fraction in heart failure with the use of estrogen[22]. Similar results have been presented by Mizushiba et al. They found that administration of estradiol post hemorrhagic shock in rats restored cardiac index to sham levels[6].

Data on survival post cardiac arrest are conflicting. It appears that women have a higher immediate death rate, but possibly a better long term outcome[35–37]. As of now it is unclear to us why levosimendan should not be used to the same extent in women as in men.

By this point it is clear that the care provided to men and women differs slightly. Our intention with this investigation is not to conclude that one group receives better treatment than the other. Instead, we are interested in whether the difference in care provided is driven by different needs. Dichotomizing on sex is most likely an oversimplification and it is clear that data is lost in this process. However, this is the foundation on which we
need to be able to individualize treatment and tailor treatment in the ICU. The question is which (to this point unknown) variables that would help us reach further.

By utilizing two different databases we get a high-resolution dataset with over 9000 patients, allowing for subgroup analyses. A limitation is the fact that we did not have access to detailed measures of organ failure on admission, which potentially could explain differences in the interventions studied. Nor did we have access to the progression of organ failure in the patients. Sequential Organ Fail Assessment score would have been an aid in interpreting the results. Further studies should include an even higher resolution dataset, including data on day-to-day progression of disease and organ failure. Residual confounders can never be ruled out in a cohort study. This is a single center study, which has implications on the external validity.

Conclusion
In this large ICU population, we found that men received more mechanical ventilation, vasoactive treatment, dialysis and inotropy as compared to women even after adjusting for available confounders. However, we did not have access to organ failure progression in this cohort, which is a major limitation. The reasons for differences in intensity of care provided between men and women might be explained by different biological mechanisms or degrees of organ dysfunction between men and women presenting with critical illness, but gender bias must also be acknowledged as a possible mechanism.

Data availability
Upon reasonable request and according to ethical approval.

Code availability
Upon reasonable request and according to ethical approval.

Received: 20 April 2021; Accepted: 16 November 2021
Published online: 03 December 2021

References
1. Mahmood, K., Eldeirawi, K. & Wahidi, M. M. Association of gender with outcomes in critically ill patients. Crit. Care 16, R92 (2012).
2. Valentin, A., Jordan, B., Lang, T., Hiesmayr, M. & Metnitz, P. G. Gender-related differences in intensive care: A multiple-center cohort study of therapeutic interventions and outcome in critically ill patients. Crit. Care Med. 31, 1901–1907 (2003).
3. Fowler, R. A. et al. Sex- and age-based differences in the delivery and outcomes of critical care. CMAJ 177, 1513–1519 (2007).
4. Vezzani, A. et al. Gender differences in case mix and outcome of critically ill patients. Gend. Med. 8, 32–39 (2011).
5. Samuelsson, C., Sjoberg, F., Karlstrom, G., Nolin, T. & Walther, S. M. Gender differences in outcome and use of resources do exist in Swedish intensive care, but to no advantage for women of premenopausal age. Crit. Care 19, 129 (2015).
6. Zettersten, E., Jaderling, G., Bell, M. & Larsson, E. Sex and gender aspects on intensive care A cohort study. J. Crit. Care 55, 22–27 (2019).
7. Knofler, M. W. et al. Female sex hormones regulate macrophage function after trauma-hemorrhage and prevent increased death rate from subsequent sepsis. Ann. Surg. 235, 105–112 (2002).
8. Knofler, M. W. et al. 17 beta-Estradiol normalizes immune responses in ovariectomized females after trauma-hemorrhage. Am. J. Physiol. Cell Physiol. 281, C1131–C1138 (2001).
9. Mizushima, Y. et al. Estradiol administration after trauma-hemorrhage improves cardiovascular and hepatocellular functions in male animals. Ann. Surg. 232, 673–679 (2000).
10. May, A. K. et al. Estradiol is associated with mortality in critically ill trauma and surgical patients. Crit. Care Med. 36, 62–68 (2008).
11. Dossett, L. A. et al. High levels of endogenous estrogens are associated with death in the critically injured adult. J. Trauma 64, 580–585 (2008).
12. Zettersten, E., Jaderling, G., Larsson, E. & Bell, M. The impact of patient sex on intensive care unit admission: A blinded randomized survey. Scand. J. Respir. Ther. 4, 14222 (2019).
13. Larsson, E., Zettersten, E., Jaderling, G., Ohlsson, A. & Bell, M. The influence of gender on ICU admittance. Scand. J. Trauma Resusc. Emerg. Med. 23, 108 (2015).
14. WHO | Gender and Genetics. WHO https://www.who.int/genomics/gender/en/ (2018).
15. Knaus, W. A. et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Curr. Opin. Crit. Care 10, 1619–1636 (1991).
16. Moreno, R. P. et al. SAPS 3—From evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med. 31, 1345–1355 (2005).
17. Pietropaoli, A. P., Glance, L. G., Oakes, D. & Fisher, S. G. Gender differences in mortality in patients with severe sepsis or septic shock. Gend. Med. 7, 422–437 (2010).
18. Park, D. W. et al. Epidemiological and clinical characteristics of community-acquired severe sepsis and septic shock: A prospective observational study in 12 university hospitals in Korea. J. Korean Med. Sci. 27, 1308–1314 (2012).
19. Erfinanda, L. et al. Estrogen-mediated upregulation of the Mas receptor contributes to sex differences in acute lung injury and lung vascular barrier regulation. Eur. Respir. J. https://doi.org/10.1183/13993003.00921-2020 (2020).
20. Pleischfischer, J., Köditz, R., Pfohl, M. & Schatz, H. Changes in proinflammatory cytokine activity after menopause. Endocr. Rev. 23, 90–119 (2002).
21. Schroder, J., Kahlke, V., Staubach, K. H., Zabel, P. & Stuber, F. Gender differences in human sepsis. Arch. Surg. 133, 1200–1205 (1998).
22. Jorga, A. et al. Estrogen rescues heart failure through estrogen receptor β activation. Biol. Sex Differ. 9, 48 (2018).
23. Li, Y. et al. Age and sex differences in vascular responsiveness in healthy and trauma patients: Contribution of estrogen receptor-mediated Rho kinase and PKC pathways. Am. J. Physiol. Heart Circ. Physiol. 306, H1105–1115 (2014).
24. Neugarten, J., Goelstaneh, L. & Kolhe, N. V. Sex differences in acute kidney injury requiring dialysis. BMC Nephrol. 19, 131 (2018).
25. Gaudry, S. et al. Acute kidney injury in critically ill: Experience of a conservative strategy. J. Crit. Care 29, 1022–1027 (2014).
26. Vaara, S. et al. Timing of RRT based on the presence of conventional indications. CJA&NT 9, 1577–1585 (2014).
27. O’Leary, J. G. et al. Gender-specific differences in baseline, peak, and delta serum creatinine: The NACSELD experience. Dig. Dis. Sci. 62, 768–776 (2017).
28. Ikeda, M. et al. Estrogen administered after cardiac arrest and cardiopulmonary resuscitation ameliorates acute kidney injury in a sex- and age-specific manner. Crit. Care 19, 332 (2015).
29. Buléon, M. et al. A single dose of estrogen during hemorrhagic shock protects against kidney injury whereas estrogen restoration in ovariectomized mice is ineffective. Sci. Rep. 10, 17240 (2020).
30. Singh, A. P., Singh, N., Pathak, D. & Bedi, P. M. S. Estradiol attenuates ischemia reperfusion-induced acute kidney injury through PPAR-γ stimulated eNOS activation in rats. Mol. Cell. Biochem. 453, 1–9 (2019).
31. Gordon, A. C. et al. Efficacy and Mechanism Evaluation. in Levosimendan to prevent acute organ dysfunction in sepsis: the LeopARDS RCT (NIHR Journals Library Copyright © Queen's Printer and Controller of HMSO 2018. This work was produced by Gordon et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK, 2018).
32. Chang, W., Xie, J. F., Xu, J. Y. & Yang, Y. Effect of levosimendan on mortality in severe sepsis and septic shock: A meta-analysis of randomised trials. BMJ Open 8, e019338 (2018).
33. Ryst, S. et al. The effect of levosimendan on survival and cardiac performance in an ischemic cardiac arrest model—A blinded randomized placebo-controlled study in swine. Resuscitation 150, 113–120 (2020).
34. Lam, C. S. P. et al. Sex differences in heart failure. Eur. Heart J. 40, 3859–3868c (2019).
35. Lam, C. S. et al. Sex differences in clinical characteristics and outcomes after myocardial infarction: Insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur. J. Heart Fail. 17, 301–312 (2015).
36. Prabhavathi, K., Selvi, K. T., Poornima, K. N. & Sarvanan, A. Role of biological sex in normal cardiac function and in its disease outcome—A review. J. Clin. Diagn. Res. 8, BE01–BE04 (2014).
37. Nehme, Z., Andrew, E., Bernard, S. & Smith, K. Sex differences in the quality-of-life and functional outcome of cardiac arrest survivors. Resuscitation 137, 21–28 (2019).

Author contributions
E.Z. and E.L. had full access to all of the data in the study and take responsibility for the integrity of the data, the accuracy of the data analysis and the decision to submit for publication. Concept and design: E.Z., E.L., G.J., M.B. Acquisition, analysis, or interpretation of data: E.L., E.Z., M.B., G.J. Drafting of the manuscript: E.Z., E.L. Critical revision of the manuscript for important intellectual content: E.Z., E.L., M.B., G.J. Statistical analysis: E.Z., E.L. Administrative technical, or material support: E.L. Supervision: E.L.

Funding
Open access funding provided by Karolinska Institute. The study was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (grant number 20150845) and The Swedish Society of Medicine (grant number 778001).

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to E.Z.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021